LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert opinion with no primary data or systematic search methodology
PubMed 28696796 · doi:10.1080/17425247.2017.1353972
What was done
This narrative review summarizes clinical data across approximately 60,000 cycles of use to describe the contraceptive efficacy, safety, and tolerability of the 19.5 mg levonorgestrel-releasing intrauterine system (LNG-IUS 12), as well as the potential influence of age, parity, and body mass index on outcomes.
What was found
The abstract reports no numerical efficacy rates, failure rates, or adverse event frequencies. It qualitatively describes LNG-IUS 12 as offering 5-year contraceptive protection with a smaller frame, narrower inserter, and lower rates of amenorrhea compared to higher-dose systems.
Why it matters
LNG-IUS 12 expands contraceptive options by combining a 5-year duration of use with a smaller frame and lower amenorrhea rates for individuals who prefer a mid-dose hormonal device.
Limits
As an expert narrative review rather than a systematic review or primary trial, the abstract provides no specific numerical data, Pearl indices, or exact participant counts, relying instead on high-level qualitative summaries.
Cited by
- supports The Kyleena intrauterine device is physically smaller in size than the Mirena intrauterine device.